X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
palbociclib (566) 566
index medicus (348) 348
oncology (343) 343
breast cancer (290) 290
humans (215) 215
female (162) 162
combination (157) 157
endocrine therapy (142) 142
fulvestrant (139) 139
letrozole (137) 137
abemaciclib (124) 124
cancer (123) 123
breast neoplasms - drug therapy (111) 111
ribociclib (110) 110
therapy (108) 108
cyclin-dependent kinase 4 - antagonists & inhibitors (104) 104
metastasis (104) 104
cyclin-dependent kinase 6 - antagonists & inhibitors (95) 95
cell cycle (93) 93
cyclin-dependent kinases (92) 92
cdk4 (87) 87
cyclin-dependent kinase 4 (82) 82
chemotherapy (81) 81
dependent kinase 4/6 (73) 73
breast neoplasms - pathology (71) 71
double-blind (71) 71
care and treatment (70) 70
postmenopausal women (69) 69
1st-line treatment (66) 66
breast-cancer (66) 66
clinical trials (64) 64
animals (63) 63
pharmacology & pharmacy (63) 63
tumors (63) 63
analysis (62) 62
pd 0332991 (62) 62
cancer therapies (58) 58
medicine & public health (57) 57
patients (57) 57
phase-i (57) 57
metastases (56) 56
kinases (55) 55
metastatic breast cancer (54) 54
erbb-2 protein (53) 53
research (53) 53
cell biology (52) 52
resistance (52) 52
cyclin-dependent kinase (51) 51
middle aged (51) 51
piperazines - pharmacology (51) 51
pyridines - pharmacology (51) 51
article (50) 50
estrogen (49) 49
survival (49) 49
cdk4/6 inhibitors (48) 48
epidermal growth factor (48) 48
expression (48) 48
cell line, tumor (47) 47
cell-cycle (47) 47
aged (46) 46
piperazines - therapeutic use (46) 46
pyridines - therapeutic use (46) 46
antineoplastic agents - therapeutic use (45) 45
antineoplastic combined chemotherapy protocols - therapeutic use (44) 44
phosphorylation (44) 44
protein kinase inhibitors - pharmacology (44) 44
women (44) 44
health aspects (43) 43
kinase 4/6 inhibitor (43) 43
adult (42) 42
protein kinase inhibitors - therapeutic use (42) 42
breast neoplasms - metabolism (41) 41
treatment outcome (41) 41
advanced breast cancer (39) 39
cdk4/6 inhibitor (39) 39
drug therapy (39) 39
inhibitors (38) 38
mice (38) 38
obstetrics & gynecology (38) 38
multicenter (37) 37
neoplasms. tumors. oncology. including cancer and carcinogens (37) 37
neutropenia (37) 37
cdk4/6 (36) 36
antineoplastic agents - pharmacology (35) 35
apoptosis (35) 35
receptors, estrogen - metabolism (35) 35
toxicity (35) 35
piperazines - administration & dosage (34) 34
pyridines - administration & dosage (34) 34
trial (34) 34
anastrozole (33) 33
tamoxifen (33) 33
cell proliferation (32) 32
womens health (32) 32
antitumor-activity (31) 31
endocrine resistance (31) 31
placebo (31) 31
review (31) 31
inhibition (30) 30
inhibitor (30) 30
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BREAST CANCER RESEARCH, ISSN 1465-5411, 09/2019, Volume 21, Issue 1, pp. 1 - 12
Background The biological effect of oral metronomic vinorelbine (mVNB) alone or in combination with endocrine therapy in patients with hormone... 
MULTICENTER | PLACEBO | Window of opportunity | CYCLOPHOSPHAMIDE | PHASE-III | Breast cancer | PROLIFERATION | Gene expression | CHEMOTHERAPY | PALBOCICLIB | EXEMESTANE | ONCOLOGY | REGULATORY T-CELLS | Metronomic | Vinorelbine | Letrozole | Usage | Genetic aspects | Drug therapy, Combination | Research | Drug therapy | Risk factors
Journal Article
by Xu, JL and Huang, F and Yao, ZC and Jia, CC and Xiong, ZY and Liang, H and Lin, N and Deng, MH
CELL COMMUNICATION AND SIGNALING, ISSN 1478-811X, 07/2019, Volume 17, Issue 1, pp. 85 - 11
BackgroundTo clarify the effects of cylcin E1 expression on HCC tumor progression, we studied the expression of cyclin E1 and inhibitory efficacy of... 
PATHWAYS | Regorafenib | TRANSCRIPTION | Hepatocellular carcinoma | SORAFENIB | Cyclin E1 | CANCER | DINACICLIB | CELL BIOLOGY | Mcl-1 | PALBOCICLIB | RESISTANCE | TUMOR-GROWTH | DEPENDENT KINASES | FLAVOPIRIDOL | Cancer cells | Development and progression | Genetic aspects | Hepatoma | Drug therapy | Health aspects | Cyclin E proteins | Apoptosis
Journal Article
NATURE COMMUNICATIONS, ISSN 2041-1723, 10/2019, Volume 10, Issue 1, pp. 1 - 15
Journal Article
Chemical Papers, ISSN 2585-7290, 12/2019, Volume 73, Issue 12, pp. 3043 - 3051
In this paper, a novel synthetic method for Palbociclib was reported. It was synthesized in eight steps from 2-(methylthio) pyrimidin-4-(3H)-one with... 
Biochemistry, general | Medicinal Chemistry | Biotechnology | Chemistry | CDK inhibitor | Synthesis | Chemistry/Food Science, general | Materials Science, general | Palbociclib | CDK | Industrial Chemistry/Chemical Engineering | Cross coupling | Bromination | Reagents | Substitution reactions | Chemical reactions | Oxidation | Chemical synthesis
Journal Article
NATURE COMMUNICATIONS, ISSN 2041-1723, 05/2019, Volume 10, Issue 1, pp. 2204 - 17
Journal Article
Journal Article
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, ISSN 1756-9966, 08/2019, Volume 38, Issue 1, pp. 380 - 13
Background Accumulating evidence demonstrates the oncogenic roles of lncRNA (long non-coding RNA) molecules in a wide variety of cancer types including glioma.... 
CELLS | Glioblastoma | Palbociclib | TUMOR | PROLIFERATION | MECHANISMS | miR-627-5p | CDK6 signaling | LUNG-CANCER | ONCOLOGY | lncRNA SNHG15 | CDK4/6 INHIBITOR | GROWTH | Microglial cells | Temozolomide resistance | NONCODING RNA SNHG15 | PROGRESSION | Cellular signal transduction | Genetic aspects | Prognosis | Research | Drug therapy | Glioblastoma multiforme | Tumorigenesis | lncRNA SNHG15/miR-627-5p/CDK6 signaling
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 10/2019, Volume 60, Issue 12, pp. 2917 - 2921
In mantle cell lymphoma (MCL), cyclin D1 combines with CDK4/6 to phosphorylate Rb, releasing a break on the G1 to S phase cell cycle. Palbociclib is a... 
bortezomib | cell cycle | palbociclib | PD 0332991 | Mantle cell lymphoma
Journal Article
BMC CANCER, ISSN 1471-2407, 01/2019, Volume 19, Issue 1, pp. 36 - 10
Journal Article
Veterinary and Comparative Oncology, ISSN 1476-5810, 12/2019, Volume 17, Issue 4, pp. 507 - 521
Therapy of canine mammary tumours (CMTs) with classical antitumour drugs is problematic, so better therapeutic options are needed. Palbociclib (PD‐0332991) is... 
canine mammary tumour | migration | CDK4/6 | cell cycle | Palbociclib | Index Medicus
Journal Article
BMC NEUROLOGY, ISSN 1471-2377, 10/2019, Volume 19, Issue 1, pp. 1 - 7
Background Palbociclib is a selective well-tolerated antineoplastic drug used in the treatment of advanced HER2-negative, estrogen-receptor positive breast... 
FULVESTRANT | Simvastatin | Palbociclib | rs4149056 | Rhabdomyolysis | CANCER | CLINICAL NEUROLOGY | CYP3A4
Journal Article
by Yuan, Y and Wen, W and Yost, SE and Xing, QH and Yan, J and Han, ES and Mortimer, J and Yim, JH
SCIENTIFIC REPORTS, ISSN 2045-2322, 05/2019, Volume 9, Issue 1, pp. 7509 - 11
A third of patients with triple negative breast cancer (TNBC) have relapsed disease within 2-5 years from initial diagnosis, leaving an unmet need for... 
TRIAL | PALBOCICLIB | IMPACT | PI3K | MULTIDISCIPLINARY SCIENCES | CDK4/6 INHIBITOR | PTEN | PHASE-II | TARGETS | PI3K/AKT/MTOR PATHWAYS | TOR protein | Cell proliferation | Phosphorylation | Therapeutic applications | AKT protein | Breast cancer | Cyclin-dependent kinase 4 | Mcl-1 protein | 1-Phosphatidylinositol 3-kinase | Metastases | Apoptosis
Journal Article
NPJ BREAST CANCER, ISSN 2374-4677, 08/2019, Volume 5, Issue 1, pp. 27 - 9
The harnessing in clinical practice of cyclin-dependent kinases 4/6 inhibitors, namely palbociclib, ribociclib, and abemaciclib, has substantially changed the... 
1ST-LINE TREATMENT | NEOADJUVANT PALBOCICLIB | ONCOLOGY | FULVESTRANT | METASTATIC BREAST-CANCER | CDK4/6 INHIBITOR | LETROZOLE | ENDOCRINE THERAPY | ABEMACICLIB | COMBINATION | PATIENT-REPORTED OUTCOMES | Cyclin-dependent kinases | Clinical medicine | Quality of life
Journal Article